Exercise program to help cancer patients during chemotherapy
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NA · Dana-Farber Cancer Institute · NCT04997096
This study tests if a 16-week online exercise program can help women with ovarian or endometrial cancer feel better during their first round of chemotherapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Dana-Farber Cancer Institute (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT04997096 on ClinicalTrials.gov |
What this trial studies
This research evaluates the feasibility of a 16-week virtually supervised aerobic and resistance exercise program for patients with ovarian or endometrial cancer undergoing first-line chemotherapy. The study compares an exercise group to a control group to assess improvements in lower extremity function, chemotherapy-induced peripheral neuropathy (CIPN), and inflammatory blood markers. Participants will engage in home-based exercise sessions via Zoom, while the control group will perform stretching exercises. The study aims to enroll approximately 30 participants.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed adults with stages III-IV ovarian or endometrial cancer receiving first-line chemotherapy.
Not a fit: Patients with pre-existing musculoskeletal, neurological, or cardiorespiratory conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance physical function and reduce side effects for patients undergoing chemotherapy.
How similar studies have performed: Other studies have shown positive outcomes with exercise interventions in cancer patients, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study Exclusion Criteria: * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Where this trial is running
Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Christina Dieli-Conwright, PhD — Dana-Farber Cancer Institute
- Study coordinator: Christina Dieli-Conwright, PhD
- Email: ChristinaM_Dieli-Conwright@dfci.harvard.edu
- Phone: (617) 582-8321
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Endometrial Cancer Stage, Aerobic Exercise